Evidence map›Paper›PMID 33300002›Full record

ArticlebioRxiv : the preprint server for biology2020

Chromatin remodeling in peripheral blood cells reflects COVID-19 symptom severity.

Nicholas S Giroux, Shengli Ding, Micah T McClain, Thomas W Burke, Elizabeth Petzold, Hong A Chung, Grecia R Palomino, Ergang Wang, Rui Xi, Shree Bose and 12 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 1 country.

Nicholas S GirouxDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC, USA.
Shengli DingDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC, USA.
Micah T McClainCenter for Applied Genomics and Precision Medicine, Duke University, Durham, NC, USA.
Thomas W BurkeCenter for Applied Genomics and Precision Medicine, Duke University, Durham, NC, USA.
Elizabeth PetzoldCenter for Applied Genomics and Precision Medicine, Duke University, Durham, NC, USA.
Hong A ChungDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC, USA.
Grecia R PalominoDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC, USA.
Ergang WangDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC, USA.
Rui XiDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC, USA.
Shree BoseDepartment of Pharmacology and Cancer Biology, School of Medicine, Duke University, Durham, NC, USA.
Tomer RotsteinDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC, USA.
Bradly P NicholsonInstitute for Medical Research, Durham, NC, USA.
Tianyi ChenDepartment of Molecular Genetics and Microbiology, School of Medicine, Duke University, Durham, NC, USA.
Ricardo HenaoCenter for Applied Genomics and Precision Medicine, Duke University, Durham, NC, USA.
Gregory D SempowskiDuke Human Vaccine Institute and Department of Medicine, School of Medicine, Duke University, Durham, NC, USA.
Thomas N DennyDuke Human Vaccine Institute and Department of Medicine, School of Medicine, Duke University, Durham, NC, USA.
Emily R KoCenter for Applied Genomics and Precision Medicine, Duke University, Durham, NC, USA.
Geoffrey S GinsburgCenter for Applied Genomics and Precision Medicine, Duke University, Durham, NC, USA.
Bryan D KraftCenter for Applied Genomics and Precision Medicine, Duke University, Durham, NC, USA.
Ephraim L TsalikCenter for Applied Genomics and Precision Medicine, Duke University, Durham, NC, USA.
Christopher W WoodsCenter for Applied Genomics and Precision Medicine, Duke University, Durham, NC, USA.
Xiling ShenDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC, USA.
Duke University · USInstitute for Medical Research · US

Funding

Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007171 · NIGMS · DUKE UNIVERSITY · PI KONTOS, CHRISTOPHER D · 1985 to 2021
$31.2M
NIAID VIROLOGY QUALITY ASSURANCE (VQA) COVID-1975N93019C00015 · NIAID · DUKE UNIVERSITY · PI DENNY, THOMAS · 2019 to 2025
$24.4M
Regional Biocontainment Laboratory (RBL)UC6AI058607 · NIAID · DUKE UNIVERSITY · PI WILLIAMS, R SANDERS · 2003 to 2005
$16.3M
Medical Scientist Training Program Training GrantT32GM145449 · NIGMS · DUKE UNIVERSITY · PI Christopher D Kontos · 2022 to 2026
$6.6M
Robust Control of the Stem Cell NicheR35GM122465 · NIGMS · TERASAKI INSTITUTE FOR BIOMEDICAL INNOVATION · PI Xiling Shen · 2017 to 2026
$5.6M
Plasma Protein Biomarker-Based Diagnostics Of Outcome In Sepsis and CAPU01AI066569 · NIAID · NATIONAL CENTER FOR GENOME RESOURCES · PI KINGSMORE, STEPHEN FRANCIS · 2005 to 2010
$2.9M
Role of S-nitrosothiols in Akt1 signaling and pneumonia resolutionK08HL130557 · NHLBI · DUKE UNIVERSITY · PI KRAFT, BRYAN D. · 2017 to 2021
$591k
NHLBI NIH HHS K08 HL130557NIAID NIH HHS 75N93019C00015NIAID NIH HHS U01 AI066569NIAID NIH HHS UC6 AI058607NIAID NIH HHS UM1 AI104681NIGMS NIH HHS R35 GM122465NIGMS NIH HHS T32 GM007171NIGMS NIH HHS T32 GM145449
6 · The paper itself

Abstract

SARS-CoV-2 infection triggers highly variable host responses and causes varying degrees of illness in humans. We sought to harness the peripheral blood mononuclear cell (PBMC) response over the course of illness to provide insight into COVID-19 physiology. We analyzed PBMCs from subjects with variable symptom severity at different stages of clinical illness before and after IgG seroconversion to SARS-CoV-2. Prior to seroconversion, PBMC transcriptomes did not distinguish symptom severity. In contrast, changes in chromatin accessibility were associated with symptom severity. Furthermore, single-cell analyses revealed evolution of the chromatin accessibility landscape and transcription factor motif occupancy for individual PBMC cell types. The most extensive remodeling occurred in CD14+ monocytes where sub-populations with distinct chromatin accessibility profiles were associated with disease severity. Our findings indicate that pre-seroconversion chromatin remodeling in certain innate immune populations is associated with divergence in symptom severity, and the identified transcription factors, regulatory elements, and downstream pathways provide potential prognostic markers for COVID-19 subjects.

Identifiers

PMID33300002
PMCPMC7724678
OpenAlexW3112884695

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.